Back to Results
First PageMeta Content
Tipranavir / Antiretroviral drug / Ritonavir / Saquinavir / Boehringer Ingelheim / Efavirenz / Abacavir / Zidovudine / Reverse-transcriptase inhibitor / Chemistry / Protease inhibitors / Organic chemistry


Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir Capsules NDA[removed]Antiviral Drugs Advisory Committee Briefing Document, April 19, 2005 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Add to Reading List

Document Date: 2005-05-18 11:35:40

Open Document

File Size: 712,76 KB

Share Result on Facebook

Company

Boehringer Ingelheim Pharmaceuticals Inc. / ABBREVIATIONS AE / Pharmacia / PIs / /

Currency

pence / /

Event

FDA Phase / /

Facility

LABORATORY EVALUATIONS OF PIVOTAL / Laboratory Adnormalities / /

MedicalCondition

HIV epidemic / HIV / AIDS / infection / Chronic / /

MedicalTreatment

Highly active antiretroviral therapy / drug delivery system / HAART / /

Organization

FDA / TIPRANAVIR ANTI-VIRAL DRUGS ADVISORY COMMITTEE / U.S. Securities and Exchange Commission / /

Person

SAE SCS SEC SEDDS SQV / Lopinavir Milligram Milliliter / Lopinavir Milligram Milliliter Cubic / /

Position

forward / /

Product

Efavirenz / zidovudine / abacavir / Inc. Tipranavir Capsules / Tipranavir Capsules / Tipranavir / /

Technology

PHARMACOKINETICS / GENOTYPE / SEDDS SQV SQV/r SOC TPV TPV/r TR µM VL WT Person exposure years Protease inhibitor Pharmacokinetics Per protocol / drug delivery system / /

SocialTag